The agreement, which came into force on February 1 and expires on March 31, 2023, aims to improve efficiency and better manage the cost of drug projects for policyholders. However, the agreement gives proponents the opportunity to design a plan that could contain certain incentives that the insurer could manage. Any insurer must take a position on this clause and the management of incentives may vary from insurer to insurer. Since 1997, there has been a cooperation agreement between the AQPP and third-party payers, but it has never provided contributions or authorizations from insurers in the province. The new cooperation agreement is the first to be concluded in Quebec between the three parties to the pharmaceutical procedure subject to medical prescription. The new agreement will apply to all those who are part of private group insurance and who purchase prescription drugs in Quebec. It will come into effect on February 1, 2020 and expire on March 1, 2023. The Nova Scotia government has expanded the role of pharmacists in the province. While pharmacists were previously allowed to prescribe medications for minor and frequent complaints and smoking cessation products, the agreement between the province and the Nova Scotia Pharmacy Association now allows pharmacists to also write prescriptions for birth control, urinary tract infections and shingles. The area of expanded practice came into force on 1 December 2019 and the policy was implemented on 1 January 2020. The agreement also contains several conditions for the regulation of pharmacy fees and pharmacy choice, including: the agreement aims to allow better control of the cost of prescription drugs in group insurance with Quebec members, including: the agreement is a step in the right direction and we will continue our discussions with all parties concerned to improve the control of drug costs and the sustainability of group insurance plans. We will keep you informed of the implementation of the new measures.
Watch out for our next communications! Historically, the use of a „reasonable and usual price“ – the application of a maximum price for a drug given by an insurer – was often a problem for the pharmacy. The new agreement now recognizes the insurer`s right to manage the developer`s plan, which involves limiting the price of a drug.